Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.49 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14195842 | 0.94 | THRA (0.51) | FDPSKDM4EGAAMEN1KMT2A | |
| SCHEMBL177168 | 0.92 | FDPS (0.54) | FDPSKDM4EGAAMEN1KMT2A | |
| SCHEMBL3923180 | 0.85 | FDPS (0.50) | FDPSKDM4EALDH1A1ALDH1A3ALDH3A1 | |
| SCHEMBL493460 | 0.85 | ALDH1A1 (0.60) | FDPSKDM4EGAAALDH1A1ALDH1A3 | |
| SCHEMBL30834674 | 0.85 | FDPS (0.67) | FDPSALDH1A1TDP1L3MBTL1MAPT | |
| SCHEMBL2821372 | 0.85 | FDPS (0.67) | FDPSALDH1A1TDP1L3MBTL1MAPT | |
| SCHEMBL4959651 | 0.84 | FDPS (0.61) | FDPSKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL29655033 | 0.84 | FDPS (0.61) | FDPSKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL28938242 | 0.83 | FDPS (0.56) | FDPSGAAALDH1A1TDP1L3MBTL1 | |
| SCHEMBL3923163 | 0.83 | CYP1A2 (0.64) | FDPSKDM4EALDH1A1ALDH1A3ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
| CN-102766099-B | There is compound and salt, preparation method and the purposes of xanthine oxidase inhibitory activity | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2015-09-23 | — | — | CN | disclosed |
| EP-1446388-B1 | 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS | STERIX LTD (GB) | 2013-01-09 | — | — | EP | disclosed |
| CN-102766099-A | Compound with xanthine oxidase inhibitory activity as well as salt, preparation methods and application thereof | UNIV SHENYANG PHARMACEUTICAL | 2012-11-07 | — | — | CN | disclosed |
| US-20110092591-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
| US-7745472-B2 | Compound | STERIX LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| WO-2009098287-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA S.A. (ES) | 2009-08-13 | — | — | WO | disclosed |
| US-20090111862-A1 | Compound | RICHTER GEDEON NYRT. (HU) | 2009-04-30 | — | — | US | disclosed |
| US-7361677-B2 | Polycyclic sulphamate compounds suitable for use as inhibitors of aromatase and/or sulphatase | STERIX, LTD. (GB) | 2008-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111862-A1 | Compound | QPCT, SQOR, SDHA | FDPS 13/4885KDM4E 257/4885GAA 3866/4885 |
| US-20110092591-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | PSEN1, PARK7, APP | FDPS 21/4885KDM4E 3491/4885GAA 356/4885 |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | FDPS 1801/4885KDM4E 1757/4885GAA 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.